[go: up one dir, main page]

AR082312A1 - Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos - Google Patents

Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos

Info

Publication number
AR082312A1
AR082312A1 ARP110102642A ARP110102642A AR082312A1 AR 082312 A1 AR082312 A1 AR 082312A1 AR P110102642 A ARP110102642 A AR P110102642A AR P110102642 A ARP110102642 A AR P110102642A AR 082312 A1 AR082312 A1 AR 082312A1
Authority
AR
Argentina
Prior art keywords
seq
metabolic disorders
pharmaceutical combination
combination composition
treat diabetes
Prior art date
Application number
ARP110102642A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082312(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of AR082312A1 publication Critical patent/AR082312A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica para administrar a un paciente que sufre desde diabetes hasta otras enfermedades metabólicas, la composición comprende: a) una forma activada potenciada de un anticuerpo contra un receptor de insulina humana, y b) una forma activada potenciada de un anticuerpo contra la NO-sintasa endotelial.Reivindicación 11: La composición farmacéutica de la reivindicación 1, caracterizada porque dicho receptor de insulina humana consiste en una secuencia seleccionada del grupo que consiste en SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3, SEQ ID Nº 4, SEQ ID Nº 5, SEQ ID Nº 6, SEQ ID Nº 7, SEQ ID Nº 8, SEQ ID Nº 9, SEQ ID Nº 10, SEQ ID Nº 11, SEQ ID Nº 12, SEQ ID Nº 13, SEQ ID Nº 14. Reivindicación 12: La composición farmacéutica de la reivindicación 1, caracterizada porque dicha NO-sintasa endotelial consiste en una secuencia provista en SEQ. ID Nº 15, SEQ ID Nº 16, SEQ ID Nº 17, SEQ ID Nº 18, SEQ ID Nº 19, SEQ ID Nº 20, SEQ ID Nº 21, SEQ ID Nº 22.
ARP110102642A 2010-07-21 2011-07-21 Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos AR082312A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами

Publications (1)

Publication Number Publication Date
AR082312A1 true AR082312A1 (es) 2012-11-28

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102642A AR082312A1 (es) 2010-07-21 2011-07-21 Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos

Country Status (30)

Country Link
US (1) US8617555B2 (es)
EP (2) EP3693018A1 (es)
JP (2) JP2013533268A (es)
KR (2) KR20180127515A (es)
CN (1) CN103118707A (es)
AR (1) AR082312A1 (es)
AU (1) AU2011281240B2 (es)
BR (1) BR112013001299A2 (es)
CA (1) CA2805961A1 (es)
CL (1) CL2013000200A1 (es)
CZ (1) CZ2013124A3 (es)
DE (1) DE112011102396T5 (es)
DK (1) DK201370089A (es)
EA (1) EA029847B1 (es)
EE (1) EE05761B1 (es)
ES (1) ES2445846R1 (es)
FI (1) FI20135152L (es)
FR (1) FR2962913A1 (es)
GB (2) GB2552405B (es)
IT (1) ITTO20110627A1 (es)
LT (1) LT5980B (es)
MX (1) MX2013000804A (es)
MY (1) MY160979A (es)
NO (1) NO20130265A1 (es)
NZ (1) NZ606964A (es)
PE (1) PE20130815A1 (es)
PH (1) PH12013500140A1 (es)
SE (1) SE1350212A1 (es)
SG (1) SG187578A1 (es)
WO (1) WO2012010966A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2008015621A (es) * 2006-06-06 2009-03-06 Oleg Iliich Epshtein Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
MX2013000543A (es) * 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
DE112011102362T5 (de) 2010-07-15 2013-04-25 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
WO2012007847A2 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
FR2962909A1 (fr) 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire
NZ606970A (en) 2010-07-21 2015-08-28 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
CN103124741A (zh) * 2010-07-21 2013-05-29 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及治疗眩晕、晕动病和植物神经-血管张力障碍的方法
KR20140012021A (ko) * 2010-08-06 2014-01-29 올레그 일리치 엡쉬테인 감염성 질환의 치료 및 예방을 위한 제약학적 복합 조성물 및 방법들
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
CA2733212C (en) * 2002-08-22 2014-01-07 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
WO2004082597A2 (en) 2003-03-14 2004-09-30 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammmation
KR20060125849A (ko) * 2004-01-20 2006-12-06 아스텔라스세이야쿠 가부시키가이샤 발기부전 치료 방법
MX2008015621A (es) 2006-06-06 2009-03-06 Oleg Iliich Epshtein Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
DE112011102362T5 (de) * 2010-07-15 2013-04-25 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
WO2012007847A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
MX2013000543A (es) * 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
FR2962909A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire
CN103124741A (zh) * 2010-07-21 2013-05-29 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及治疗眩晕、晕动病和植物神经-血管张力障碍的方法

Also Published As

Publication number Publication date
EP2595658A2 (en) 2013-05-29
FI20135152A7 (fi) 2013-02-21
PH12013500140A1 (en) 2013-03-11
GB2496799B (en) 2017-11-22
MY160979A (en) 2017-03-31
GB2552405B (en) 2018-05-30
CN103118707A (zh) 2013-05-22
EA029847B1 (ru) 2018-05-31
EA201300124A1 (ru) 2013-12-30
US20130064824A1 (en) 2013-03-14
JP2016222684A (ja) 2016-12-28
EP3693018A1 (en) 2020-08-12
LT5980B (lt) 2013-12-27
MX2013000804A (es) 2013-10-28
FR2962913A1 (fr) 2012-01-27
CA2805961A1 (en) 2012-01-26
NO20130265A1 (no) 2013-04-18
PE20130815A1 (es) 2013-07-18
KR20180127515A (ko) 2018-11-28
JP2013533268A (ja) 2013-08-22
AU2011281240B2 (en) 2016-07-07
FI20135152L (fi) 2013-02-21
EE201300007A (et) 2013-08-15
GB2496799A (en) 2013-05-22
US8617555B2 (en) 2013-12-31
CL2013000200A1 (es) 2015-01-23
KR20130103486A (ko) 2013-09-23
WO2012010966A3 (en) 2012-03-29
GB201707872D0 (en) 2017-06-28
AU2011281240A1 (en) 2013-03-07
SE1350212A1 (sv) 2013-04-22
ES2445846R1 (es) 2015-01-02
ITTO20110627A1 (it) 2012-01-22
EE05761B1 (et) 2016-03-15
DK201370089A (en) 2013-02-19
SG187578A1 (en) 2013-03-28
LT2013018A (lt) 2013-10-25
ES2445846A2 (es) 2014-03-05
DE112011102396T5 (de) 2013-05-02
CZ2013124A3 (cs) 2013-06-12
BR112013001299A2 (pt) 2017-11-21
GB201302924D0 (en) 2013-04-03
WO2012010966A2 (en) 2012-01-26
NZ606964A (en) 2015-08-28
GB2552405A (en) 2018-01-24

Similar Documents

Publication Publication Date Title
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
EP4600271A3 (en) Bioactive molecule conjugate, preparation method and use thereof
WO2010036918A3 (en) Intracellular dna receptor
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
AU2011328009A8 (en) Compounds and methods for treating pain
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
MX358991B (es) Uso de moleculas de enlace a la semaforina-4d para promover la neurogenesis despues de la apoplejia.
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
PH12013500111A1 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas

Legal Events

Date Code Title Description
FC Refusal